

nexus/ag



80% faster

QUARTERLY STATEMENT
01st January to 30st September 2024

Financial Highlights for the 3rd Quarter 2024 and 2023

	30/09/2024	30/09/2023	Change
Sales and operating result	KEUR	KEUR	(in %)
Sales	190,805	171,266	11.4
Segment revenues NEXUS / DE (unconsolidated)	63,723	56,577	12.6
Segment revenues NEXUS / DIS (unconsolidated)	51,482	39,878	29.1
Segment revenues NEXUS / ROE (unconsolidated)	86,677	83,122	4.3
Domestic sales	107,423	90,473	18.7
Sales in foreign countries	83,382	80,793	3.2
EBITDA	40,856	35,454	15.2
EBITA	31,743	26,583	19.4
EBIT	27,179	22,352	21.6
EBT	28,034	23,706	18.3
Consolidated net income	20,267	17,465	16.0
Earnings per share (undiluted/diluted) in EUR	1.18	1.02	15.7
Ongoing development costs and depreciations			
Capitalization of software developments	3,270	2,685	21.8
Total depreciation	13,677	13,103	4.4
Acquisition-related depreciation from purchase price allocation	4,564	4,231	7.9
Assets and equity capital			
Non-current assets	239,871	243,957 ¹⁾	-1.7
Current assets	175,475	167,759 ¹⁾	4.6
Liquid assets (incl. shortterm finance disposition)	102,543	97,434 ¹⁾	5.2
Equity capital	269,205	258,582 ¹⁾	4.1
Share price (closing price, Xetra, in EUR)	55.50	51.70	7.4
Employees (quarterly average)	1,853	1,640	13.0

¹⁾ Key date 31/12/2023

As rounded figures are used in this report, it is possible that the totals and calculated percentage figures may vary slightly.

Letter to our Shareholders

Dear Shareholders:

We can once again present very pleasing figures in the third quarter of 2024.

In the first nine months, we were able to largely shield ourselves from the current crises and industry problems and once again realize **strong growth in business figures**. This development is not entirely self-evident, especially when we consider the current economic situation in many countries and the problem reports of our competitors.

On the contrary: we even see very **pleasing potential** in the outlook for the future, which we would like to see.

These include the many national **digitization projects**, such as the health reform approved by the German Parliament in October. The new case and retention lump sums, the introduction of service groups and quality criteria as well as the establishment of cross-sector care facilities create substantial **requirements for HIS systems** and ensure a high degree of capacity utilization. We see digitization projects in healthcare that affect our business in one way or another in almost all the countries where we are involved. In addition, **replacement purchases** for discontinued HIS systems will be put out to tender, which will also keep us busy in the coming months and years.

We have **positioned** ourselves **strongly** among **competitors** and are working on numerous **development projects** aimed at better aligning our products with clinical processes. We are continuing to develop the **topics of** "patient journey", "AI support" and "diagnosis standardization" and are focusing our investments on **innovation projects** such as NEXUS / ADVANCED REPORTING and developments to facilitate SAP IS-H / Oracle Cerner i.s.h.med replacements. We are also **focusing** on **AI integration**: Our goal is to integrate AI functionalities **directly** into the software processes of the users and thereby achieve rapid implementation of new AI functions in daily practice.

We are very confident that the **innovations** and **product enhancements** will **prove their worth**. This clearly demonstrates our commitment to providing health facilities with software that reduces documentation times by 80%. Although we are putting a strain on our capacities and cost base in the short and medium term, we are encountering a market that demands improvement through digitalization and depends on it: There is no better reason to invest.

Trend of Business

We are therefore very pleased that we have been able to successfully continue our **strong growth history** in spite of these considerable investments in the first nine months of 2024.

Our sales increased compared to the previous year by approx. **11.4% to KEUR 190,805** in the first nine months. **EBITDA** reached **KEUR 40,856** and consequently increased by **15.2%**. Our **earnings before interest and taxes (EBIT)** increased

In the same period by approx. **21.6%** to KEUR 27,179 and the **EBT** by **18.3%** to KEUR 28,034. The **result per share** increased by **15.7%** from EUR 1.02 (9 months 2023) to EUR 1.18. The **operating cash flow** in the first nine months of 2024 amounted to **KEUR 27,716** following KEUR 29,140 (-4.9%) in the same period last year. Reasons for the lower cash flow are mainly due to the high tax payments relating to other periods in the last quarter. Without these payments, the cash flow as of 30/09/2024 would have been approx. **MEUR 32** (+10%). Our **liquidity position** was approx. **MEUR 103** as of 30/09/2024.

The **sales figures** do not include sales from company acquisitions in the current year. On the other hand, **consolidation effects** from the company acquisitions of the past year are taken into account. Excluding their sales and earnings from the first nine months of 2024, the NEXUS Group would have increased sales by approx. 8.1% without these companies. The increase in EBIT would have been 20.3%. The other consolidation effects are not included therein. We spent a total of KEUR 2,021 on the **integration** of the acquired companies in 2024.

Currency effects were mainly due to the stronger Swiss franc and Polish zloty compared to the previous year. These effects contributed a total of KEUR 1,913 to sales and KEUR 379 to EBITDA.



— Dr. Ingo Behrendt, Chief Executive Officer (CEO)

Market, Products and Projects

We are very proud that we were able to achieve these strong results while at the same time realizing pleasing sales successes. We have already won major projects in Germany, France and Austria in the first nine months of 2024. We have been particularly successful in the tendered HIS replacements in Germany (SAP IS-H and Oracle i.s.h.med-Systems) and in France (DOPASYS).

We were also able to acquire some **interesting new customers** in the third quarter. These include Hospital Information Act (KHZG) projects in Germany, managed service projects with existing customers, gastroenterological and ophthalmological projects in **Belgium** and **Switzerland** as well as orders in Ireland and Spain.

On the **project** side, we continue to be involved in intensive implementation work. Many major projects are in the roll-out phase and new projects are in the implementation phase. We have **integrated many innovation topics** into the latter, which still involve development work.

Acquisitions

We did not make any new acquisitions in the first nine months of the current year. It was not until 01/10/2024 that we acquired 100% of one of the leading providers of innovative solutions in the field of endoscopy and cardiology diagnostics, i.e., the British company **HD Clinical Ltd.** With HD Clinical, we have gained a recognized and internationally active **team of experts** for structured interpretation and image processing, thereby **strengthening** our **European market position** in software for internal medicine. HD Clinical has significantly expanded its market position in recent months: The Scottish health service NHS and the Irish health authority HSE selected HD Clinical's SOLUS software solution as part of a national tender for an endoscopy diagnostic system. We expect the collaboration with this company, which employs approximately 50 people in England and Ireland, to provide substantial product and cost synergies.

On 22/10/2024, we acquired the "Laboratory Information System" business unit with the product **LABSOFT** from the Spanish-based company "NEXUS INFORMATION SYSTEMS S.A." as part of an asset deal. With 22 employees, the company supplies Spanish hospitals with a laboratory information system. We also expect significant synergies in this case, in particular with the NEXUS / laboratory product area. Both companies and products fit perfectly into the **product strategy** of the respective areas.

We are employing **significant resources** on **realigning** and **integrating** these new teams. However, we are convinced that these investments are well spent and the associated market and portfolio expansions will significantly strengthen our position in the e-health market.

OUTLOOK: Remain Bold

The year 2024 has been very challenging and successful until now. With an approx. **11%** increase in sales and a 22% increase in EBIT, we have demonstrated strong continuation of our uninterrupted growth.

The dynamic that we are experiencing in our field is certainly outstanding this year. This applies to the **number and amount of new orders** that we have received in recent months, but also to the strong changes we see in our customers and the market. Doing justice to this at the same time is a challenge that we will have to face in the future. This means that we need to **invest** in our products, structure and international collaboration to gain market share and improve margins: This is a challenge that requires courage and long-term planning.

We have had a lot of success with our strategy in recent years and now want to increase the pace even further. The Nexus team is firmly committed to this and is looking forward to the task.

Warm regards,




Dr. Ingo Behrendt

Chief Executive Officer


Highlights Q3 2024 – Business development

- + Strong sales growth of 11.4% in the first nine months of 2024
- + Work on significant new orders started with innovation shares
- + Company/business acquisitions in England, Ireland and Spain

2013 to 2024 __ Group Sales (9 months) in KEUR



2013 to 2024 __ EBT (9 months) in KEUR



Interim Annual Report

Report about the profit, financial and asset situation

NEXUS Group sales increased from KEUR 171,266 to KEUR 190,805 (+11.4%) in the first nine months of the year 2024. The stable, positive sales development of NEXUS Group of recent years could be continued with that.

In the NEXUS / ROE segment, unconsolidated sales increased by 4.3%, totaling around KEUR 86,677 (9M 2023: KEUR 83,122). In the NEXUS / DE segment, sales increased from KEUR 56,577 to KEUR 63,723 (+12.6%). Sales of KEUR 51,482 were achieved in the NEXUS / DIS segment after KEUR 39,878 in the comparison period (+29.1%).

In terms of regional development of sales, we were able to increase sales in Germany by 18.7% to KEUR 107,423 (9M 2023: KEUR 90,473). In international business, we achieved sales of KEUR 83,382 in the first nine months of the year 2024 compared to KEUR 80,793 in the previous year (+3.2%). Sales growth in Switzerland/Liechtenstein (+8.4%), the Netherlands (+5.4%) and Austria (+23.6%) were very strong. Sales development in France (-0.1%) and Poland (-22.8%) was slightly subdued, partly due to SaaS contracts and one-off hardware sales in the previous year.

Consolidated earnings before income interest and taxes (EBIT) developed very positively. They improved by 21.6% to KEUR 27,179 (9M 2023: KEUR 22,352). A value of KEUR 31,743 was achieved in EBITA and consequently was 19.4% over the value of previous year (9M 2023: KEUR 26,583). EBITDA reached KEUR 40,856 in the first nine months of the year 2024 (9M 2023: KEUR 35,454) and consequently was 15.2% higher than in the previous year.

Cash flow from operating activities amounted to KEUR 27,716 (9M 2023: KEUR 29,140) in the first nine months of the year 2024, which is 4.9% lower than in the previous year. Higher tax payments and the increasing of receivables and other assets have impacted cash flow from operating activities.



The consolidated net income increased by 16.0% and amounted to KEUR 20,267 in the first nine months of the year 2024 following KEUR 17,465 (9M-2023). The undiluted result per share amounted to EUR 1.18 (previous year: EUR 1.02) diluted: EUR 1.18 (previous year: EUR 1.02). Cash resources including short-term financial assets amounted to KEUR 102,543 on 30/09/2024 (30/09/2023: KEUR 98,830).

Investments in tangible and intangible assets were made in the amount of KEUR 5,643 in the first nine months of the year 2024 (9M 2023: KEUR 7,162). This includes KEUR 3,270 (9M 2023: KEUR -101) for capitalizing software developments.

The balance sheet total increased from KEUR 399,711 to KEUR 415,345 compared to 30/09/2023 (+3.9%). Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 190,542 following previously KEUR 196,068 (31/12/2023). Receivables from customers amount to KEUR 31,923 following KEUR 30,938 on 30/09/2023.

EMPLOYEES

NEXUS Group employed an average of 1,853 people in the first nine months (9M 2023: 1,640 employees).



CHANGES IN OWNERSHIP INTEREST

The following changes were implemented in the ownership interest structure:

- + Nexus AG acquired the remaining 49% of the shares in the subsidiary ITR Software GmbH, Lindenberg im Allgäu, from the existing option agreement on 27/03/2024.
- + RVC Medical IT N.V., Antwerp (Belgium), was renamed Nexus Enterprise Diagnostics N.V., Antwerp (Belgium), on 03/04/2024.
- + RVC Medical IT Holding B.V., Amersfoort (Netherlands), was renamed Nexus Enterprise Diagnostics Holding B.V., Amersfoort (Netherlands), on 03/04/2024.
- + RVC Medical IT B.V., Amersfoort (Netherlands), was renamed Nexus Enterprise Diagnostics B.V., Amersfoort (Netherlands), on 03/04/2024.
- + Nexus AG acquired the remaining 5.99% of the shares in RVC Medical IT Holding B.V., Amersfoort (Netherlands), from the existing option agreement on 15/04/2024.
- + NEXUS Schweiz AG, Schenkon (Switzerland), acquired a further 20% of the shares in onelCT AG, Wallisellen (Switzerland), from the existing option agreement on 16/04/2024.
- + Nexus AG acquired a further 15.3% of the shares in IFMS GmbH, Saarbrücken, from the existing option agreement on 18/04/2024.
- + Nexus AG acquired the remaining 14.7% of the shares in IFMS GmbH, Saarbrücken, from the existing option agreement on 22/05/2024.
- + Nexus AG acquired a further 1.13% of the shares in ifa systems AG, Frechen on 24/05/2024.

- + arkandus GmbH, Peißenberg, was merged with ifa systems AG, Frechen, with effect from 01/01/2024 by merger agreement dated 29/05/2024.
- + NEXUS Schweiz AG, Schenkon (Switzerland), acquired a further 27.78% of the shares in ANT-Informatik AG, Zürich (Switzerland), from the existing option agreement on 06/06/2024.
- + NEXUS / DIS GmbH, Frankfurt am Main, was renamed NEXUS / CMC GmbH, Frankfurt am Main, on 19.06.2024.
- + The registered office of NEXUS / SCHAUF GmbH was moved to Donaueschingen on 02/07/2024.
- + NEXUS Schweiz AG, Schenkon (Switzerland), acquired the remaining 20% of the Shares in highsystems AG, Zürich (Switzerland) on 08/07/2024.
- + Nexus AG acquired the remaining 25% of the shares in NEXUS / SCHAUF GmbH, Donaueschingen, from the existing option agreement on 23/09/2024

EVENTS AFTER 30/09/2024

- + Nexus AG acquired 100% of HD Clinical Ltd, Bishop's Stortford (England), on 01/10/2024.
- + Nexus AG acquired 100 % of HD Clinical Ireland Ltd., Dublin (Ireland), on 01/10/2024. The shares are held indirectly by HD Clinical Ltd, Bishop's Stortford (England).
- + NEXUS SISINF SL, Sabadell (Spain), acquired the business segment "Laboratory information system" of NEXUS Information Technology SA, Spain, as part of an asset deal on 22/10/2024.

SALES BY TYPE

	01/01- 30/09/2024	01/01- 30/09/2023	Change	01/07- 30/09/2024	01/07- 30/09/2023	Change
	KEUR	KEUR	%	KEUR	KEUR	%
Service	48,825	44,392	10.0	14,901	14,609	2.0
Maintenance and other recurring revenue	104,043	88,324	17.8	34,994	31,254	12.0
Licenses	26,710	26,869	-0.6	9,888	8,970	10.2
Supply	11,227	11,680	-3.9	3,357	4,591	-26.9
Total	190,805	171,266	11.4	63,140	59,424	6.3

SALES BY REGION

	01/01/2024- 30/09/2024	01/01/2023- 30/09/2023	Change	01/07/2024- 30/09/2024	01/07/2023- 30/09/2023	Change
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	107,423	90,473	18.7	35,991	32,147	12.0
Switzerland /Lichtenstein	41,307	38,091	8.4	13,171	12,776	3.1
Netherlands	20,142	19,114	5.4	6,173	6,926	-10.9
Polen	6,517	8,447	-22.8	2,405	3,168	-24.1
France	5,486	5,493	-0.1	1,722	1,668	3.2
Austria	4,037	3,265	23.6	1,901	613	210.1
Other countries	5,893	6,383	-7.7	1,777	2,126	-16.4
Total	190,805	171,266	11.4	63,140	59,424	6.3

SALES BY OPERATING SEGMENTS

	NEXUS / DE		NEXUS / DIS		NEXUS / ROE		Consolidation		Group	
	01/01/2024	01/01/2023	01/01/2024	01/01/2023	01/01/2024	01/01/2023	01/01/2024	01/01/2023	01/01/2024	01/01/2023
	30/09/2024	30/09/2023	30/09/2024	30/09/2023	30/09/2024	30/09/2023	30/09/2024	30/09/2023	30/09/2024	30/09/2023
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Sales to third parties	61,683	54,577	45,738	35,782	83,385	80,907	—	—	190,805	171,266
Sales between segments	2,040	2,000	5,744	4,096	3,292	2,215	-11,076	-8,311	—	—
Segment revenues	63,723	56,577	51,482	39,878	86,677	83,122	-11,076	-8,311	190,805	171,266

__ Group Information

CHANCES AND RISKS REPORT

Please refer to the explanations in the Annual Report of 31/12/2023 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

ACCOUNTING AND VALUATION

METHODS

This interim report of the NEXUS Group of 30/09/2024 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account. The regulations of IAS 34 were observed in the interim report of 30/09/2024. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Notes to the Group Financial Report 2023. The same accounting and valuation methods were used in the Group Financial Report for the business year 2023. The report has not been audited.

Stock Market and Financial Data

Frankfurt stock exchange
stock prices (5-year period)



Investor Relations – Successful Together!

We rely on transparent, regular and timely communication in dialog with the capital market. Our goal is to build trust and work together with our investors on the success of NEXUS. We provide our investors a wide range of opportunities to exchange ideas at conferences, road shows and one-on-one meetings.

Stock Market Prices

- + **Initial listing on 02/01/2024: 58.70 EUR**
- + **Highest price on 21/05/2024: 62.60 EUR**
- + **Stock market capitalization on 30/09/2024: 960.24 Mio. EUR**
- + **Closing price on 30/09/2024: 55.50 EUR**

Company Profile

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules, we have a unique broad and interoperable product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families.

NEXUS employs approx. 1,980 people, is present in nine European countries with its own sites and serves customers in an additional 71 countries, partly via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.

Melanie Ilic

Investor Relations

Phone: +49 771 22960-260


Fax: +49 771 22960-226

E-Mail: ir@nexus-ag.de



User-friendly thanks to an easily customizable interface.

We ensure that users find their way around easily in all modules thanks to a uniform user experience platform. We provide a unique user experience with our modern "Workspace Navigation", which enables more intuitive and faster use.



modular

individual



Consolidated Profit and Loss Account

	01/01/2024- 30/09/2024	01/01/2023- 30/09/2023	01/07/2024- 30/09/2024	01/07/2023- 30/09/2023
	KEUR	KEUR	KEUR	KEUR
Revenue	190,805	171,266	63,140	59,424
Capitalized development costs	3,270	2,685	1,090	814
Other operating income	5,305	3,895	1,792	2,181
Cost of goods sold	30,738	29,441	9,137	10,902
Staff costs	111,118	97,521	36,362	33,410
Impairment Loss on Financial Assets	75	-27	-69	-95
Other operating expenses	16,593	15,457	5,184	5,023
EBITDA	40,856	35,454	15,408	13,179
Depreciation	13,677	13,103	4,639	4,715
EBIT	27,179	22,352	10,769	8,465
Financial income	2,828	2,191	920	838
Financial expenses	1,973	837	590	326
EBT	28,034	23,706	11,099	8,977
Taxes	7,767	6,241	3,214	2,246
Consolidated net income	20,267	17,465	7,885	6,731
Consolidated net income apportioned to:				
– Nexus AG shareholders	20,300	17,566	7,901	6,730
– Non-controlling interests	-33	-101	-16	1
Consolidated earnings per share				
Weighted average (undiluted) of issued shares in circulation (in thousands)	17,260	17,243	17,249	17,272
Weighted average (diluted) of issued shares in circulation (in thousands)	17,266	17,253	17,253	17,272
Undiluted in EUR	1.18	1.02	0.46	0.39
Diluted in EUR	1.18	1.02	0.46	0.39

Consolidated Balance Sheet

ASSETS	30/09/2024	30/09/2023	31/12/2023
Non-current assets	KEUR	KEUR	KEUR
Goodwill	135,023	138,403	135,592
Other intangible assets	65,621	69,936	69,188
Fixed assets	12,480	13,105	13,148
Right-of-use assets	19,517	19,264	19,734
Contract assets	49	73	50
Deferred tax assets	4,169	2,233	3,267
Other financial assets	2,048	1,973	2,030
Trade and other receivables	964	-	948
Total non-current assets	239,871	244,988	243,957
Current assets			
Inventories	4,093	3,452	3,240
Trade and other receivables	30,958	30,938	46,083
Contract assets	20,906	10,989	11,078
Other non-financial assets	5,967	5,315	3,614
Income tax receivables	1,434	1,409	1,249
Other financial assets	94,574	90,789	85,061
Cash and cash equivalents	17,543	11,830	17,434
Total current assets	175,475	154,723	167,759
Total assets	415,345	399,711	411,716

LIABILITIES	30/09/2024	30/09/2023	31/12/2023
Equity	KEUR	KEUR	KEUR
Subscribed capital	17,275	17,275	17,275
Capital reserves	103,222	103,915	103,089
Retained earnings	147,791	126,002	131,913
Other comprehensive income	-392	1,534	3,397
Capital redemption reserve	-2,055	-823	-581
Shareholders' equity attributable to parent	265,841	247,902	255,093
Non-controlling interests	3,364	3,699	3,489
Total equity	269,205	251,601	258,582
Non-current liabilities			
Pension obligations	13,343	9,481	8,959
Deferred tax liabilities	14,271	14,890	11,979
Other financial liabilities	29,381	30,935	30,335
Lease liabilities	15,283	15,216	15,438
Accrued liabilities	195	321	198
Total non-current liabilities	72,473	70,844	66,909
Current liabilities			
Accrued liabilities	3,486	2,972	4,086
Financial liabilities	-	510	-
Deferred liabilities	18,613	16,203	18,170
Income tax liabilities	7,273	9,319	11,268
Other non-financial liabilities	4,842	4,571	5,929
Trade payables	5,797	7,262	8,740
Contract liabilities	26,814	25,426	24,040
Other financial liabilities	1,814	6,477	9,185
Lease liabilities	5,027	4,525	4,807
Total current liabilities	73,666	77,266	86,225
Balance sheet total	415,345	399,711	411,716

Consolidated Cash Flow Statement

	01/01/2024-30/09/2024	01/01/2023-30/09/2023
1. Cash flow from operating activities	KEUR	KEUR
EBIT	27,179	22,352
Depreciation (+)/amortization (-) on intangible assets and fixed assets	9,509	9,285
Depreciation (+) on rights of use leased assets	4,169	3,818
Other non-operating expenses (-)/income (+)	-1,352	405
Increase (-)/decrease (+) in inventory	-864	-1,078
Gains (-)/losses (+) on the disposal of assets and investments	-21	-
Increase (-)/decrease (+) in receivables and other assets	-5,818	590
Increase (+)/decrease (-) in provisions	547	-1,456
Increase (+)/decrease (-) in liabilities	4,308	-698
Interest paid (-) / interest received (+)	1,982	1,849
Income taxes paid (-) / income tax refunds (+)	-11,922	-5,927
	27,716	29,140
2. Cash flow from investment activities		
Payments (-) for investments in intangible assets and property, plant and equipment	-5,643	-7,162
Payments (-) for the acquisition of consolidated companies less the funds acquired	-	-18,902
Proceeds (+) from the disposal of fixed assets	47	-
Payments (-)/proceeds (+) from the acquisition / divestment of shortterm financial dispositions	-5,000	3,000
	-10,596	-23,064
3. Cash flow from financing activities		
Payments (-) for purchase of non-controlling interests for already consolidated companies	-8,025	-786
Payments (-) for redemption of lease liabilities	-4,047	-4,146
Payments (-) for redemption of loan liabilities	-	-5,051
Dividends paid (-)	-3,798	-3,620
Dividends paid to non-controlling interests (-)	-	-134
Payments (-) for the purchase of treasury stock	-1,491	-743
Proceeds (+) from the sale of treasury stock	150	16
	-17,210	-14,464
Change in cash and cash equivalents	-90	-8,388
Effect of exchange rate changes on cash and cash equivalents	199	199
Cash and cash equivalents at the start of the period	17,434	20,019
Cash and cash equivalents at the end of the period	17,543	11,830
Composition of cash and cash equivalents		
Cash and bank balances	17,543	11,830
Shortterm financial dispositions	85,000	87,000
Cash and bank balances incl. shortterm financial disposition	102,543	98,830

1. SEASONAL INFLUENCES ON BUSINESS ACTIVITIES

As part of the NEXUS Group's operating activities, there are seasonal effects due to the receipt of maintenance revenue in the first quarter of each financial year (the effects on earnings of the corresponding incoming payments are recognised over the financial year) and the significantly higher demand and project invoicing in the fourth quarter of each financial year.

__ Statement from the Legal Representatives

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group and the interim management report of the group, which includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 05/11/2024

Nexus AG

The Executive Board

Nexus AG, Irmastraße 1, 78166 Donaueschingen

Tel. +49 771 22960-0, Fax +49 771 22960-226

www.nexus-ag.de, info@nexus-ag.de



nexus/ag

Nexus AG, Irmastraße 1, 78166 Donaueschingen
Tel.: +49 771 22960-0, info@nexus-ag.de
www.nexus-ehealth.com